- Anavex Life Sciences Corp (NASDAQ:AVXL) has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson's Disease Dementia (PDD) study at the AD/PD 2022 International Conference.
- MDS-UPDRS1 Total score improved significantly by -14.51 for patients treated with ANAVEX2-73 high oral once-daily dose compared to placebo.
- The improvement is clinically relevant, corresponding to a relative improvement of 18.9% over 14 weeks.
- Also Read: Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals.
- Balanced and global improvements were observed within all MDS-UPDRS sub-scores Part I-IV:
- SIGMAR1 mRNA expression significantly increased in ANAVEX2-73-treated patients vs. placebo over the course of treatment and was significantly associated with improvements of MDS-UPDRS scores and cognitive efficacy endpoints CDR system.
- Price Action: AVXL shares are up 5.06% at $10.59 during the market session on the last check Tuesday.
